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Subject Index 
A 
abciximab, 1379 
ACC staff, 1401 
ACC/AHA guidelines 
for implantation of cardiac pacemakers and 
antiarrhythmic devices, 1368 
for the management of patients with acute 
myocardial infarction, 1332, 1337. See also 
Myocardial infarction 
ACC/AHA statement "'Guidelines for the Early 
Management of Patients with Acute 
Myocardial Infarction," 1336-1337 
Acid-base disturbances in ventricular fibrillation, 
1364 
ACLS. 1337 
ACT. 1379 
Action plan, 1338 
Activity levels 
in hospital, 1354-1355 
prior, return to, 1400t, 1400-1401 
Acute coronary syndrome, 1340, 1373 
identification of patient with, 1357 
Acute Infarction Ramipril Efficacy trial. See AIRE 
trial 
Acute myocardial infarction. See Myocardial 
infarction 
Adenosine, 1386 
Admitting orders, 1354, 1355t 
Adverse events 
monitoring for, 1354 
protection against, 1354 
PTCA effects on, 1350 
treatment of, in hospital, 1356 
Afterload 
increasing of, 1360 
reduction of, 1359, 1362, 1372 
Afterload-reducing a ents, 1335 
Age, 1349 
atrial fibrillation incidence and, 1363 
mortality rates related to, thrombolytic therapy 
effects on, 1348 
Valsalva maneuver and, 1354, 1355 
Agitation, 1356 
AHA, 1399 
staff, 1401 
Step I diet, 1395 
step II diet, i395 
AHA statement, "Aspirin as a Therapeutic Agent 
in Cardiovascular Disease," 1373 
Air travel, 1401 
AIRE (Acute Infarction Ramipril Eflicacyl trial, 
1397 
Alteplase, 1334, 1349, 1379. 1382 
combined with 
aspirin, 1344 
heparin, 1376. 1377. 1378. 1379 
streptokinase, 1376 
compared with 
aspirin and heparin, 1352-1353 
other thrombolytic agents. 1376 
PTCA, 135{/, 1351 
dosing regimen for, 1375 
clficacy in acute myocardial infarction, 1375 
in ST-segment depression, cffect on mortality 
rates, 1353 
American College of Cardiology. See ACC; 
ACC/AHA 
American College of Chest Physicians (ACCP), 
1373 
American Fertility Society. 1399 
American Heart Association. See ACC/AHA; AHA 
Amiodarone. 1335, 1364 
pharmacology, 1381 
for secondary prevention, 1399 
for ventricular fibrillation, 1365 
for ventricular tachycardia, 1364, 1365 
Amrinone, 1385, 1385t 
Analgesia, 1333, 1334, 1335, 1343. See also specific 
agent 
in hospital, 1355-1356 
Aneurysm, left ventricular, 1371 
Angina pectoris, 1345, 1359, 1387. See also Chest 
discomfort 
post-MI, refractory,, intra-aortic balloon 
counterpulsation in, 1362 
unstable, 1354 
abciximab in treatment of, 1379 
heparin for, 138{I 
in ST-segment depression, 1353 
thrombolytic therapy in, 1352-1353 
without ST-segment elevation, 1352 
Angiography, 1393 
in coronary artery, disease. 13711 
early 
in non-ST-segment elevation or bundle branch 
block, 1352-1354 
in ST-segment elevation or bundle branch 
block, 1351 
after myocardial infarction, I392 
in nondiagnostic ECG changes, 1353 
in survivor of myocardial infarction ot receiving 
thrombolytic therapy. 1392 
after thrombolytic therapy, 1392 
use after first 24 hours, 1334-1335 
Angioplasty, percutaneous transluminal cnmnary 
(PTCA), 1335, 1337, 1359, 1378. 14111 
for accelerated i ioventricular rhythm, 1365 
adjuvant, after failed thmmbolytic therapy. 1393 
for cardiogenic shock, 1360 
effect on clinical outcome, 1353 
failed, coronary' artery bypass graft surgery' after, 
1369 
heparin with, 1334 
with intra-aortic balloon pump, 1363 
in left ventricular dysfunction. 1359 
possible, after myocardial infarction, 1392 
primary', 1333. 1340 
applicabili~, of, 1351 
heparin use in, 1379 
recommendations. 1348-1351 
in right vcntrieular ischemia/infarction, 1361 
results of, 135I 
after thrombolytic therapy. 1392, 1393-1395 
use rates, 1377 
Angiotensin-converting e zyme (ACE) inhibitors, 
1335, 1337. 1372. See also specific agent 
contraindications to, 1383 
dosage, 1383 
recommendations, 1382-1383 
f~r secondary, prevention, 1397 
use 
after first 24 hours, 1334 
during first 24 hours, 1334 
Anistreplase 
compared with other thrombolytic agents, 1376 
efficacy in acute myocardial infarction, 1375 
reuse of. 1376 
use of heparin with, 1377-1378 
Anterior myocardial infarction 
largc, 1334 
thrombolytic therapy for, 1346 
Antiarrhythmic agents, 1380. See also specific 
agent; specific type of agent 
amiodarone, 1381 
for atrial fibrillation, 1364 
,8-adrenoceptor blockers, 1381 
bretylium, 1380 1381 
lidocaine, 1380 
procainamide, 1381 
prophylactic, 1334, 1356 
for ventricular fibrillation, 1365 
for secondary prevention, 1399 
Anticoagulation. See also 
Antithrombotics/antocoagulants; specific 
agent 
end point, 1373 
Anti-inflammatory drugs, nonsteroidal, 1359 
Anti-ischemic nterventions, 1343 
Antioxidants, for secondary, prevention, 1398 
Antiplatelet agents, 1344, 1373-1374, 1396. See also 
specific agent 
Antithrombin lIl (ATIII), 1378 
Antithrombotics/anticoagulants, 13351358. See 
also specific agent 
heparin, 1377-1380 
hirudin, 13811 
for secondary, prevention, 1398 
Anxiety, 1334 
decrease in, 1356 
sympathetic drive and, 1355 
Anxiolytics, 1354, 1355-1356 
for nicotine withdrawal, 1356 
APSAC, comparison with other thrombolytic 
agents, 1375, 1375t 
aPT[ testing, 1377, 1378 
Arrhythmias. See also Antiarrhythmic Agents; 
Rhythm disturbances 
detection of, 1354. See also Electrocardiography 
fatal. 1337 
mortality rates associated with, digitalis effects 
on, 1386 
reperfusion, 1365 
vcntricular, 1354 
assessment of, 1391 
classification of, 1365 
procainamide for. 1381 
Arterial monitoring, invasive, 1354 
Arterial pressure, in left ventricular dysfunction, 
1359 
Aspirin, 1333, 1335, 1352, 1353, 1354, 1373, 1377, 
13811 
for chest discomfort, 1335, 1358 
combined with 
streptnkinase, 1375 
thrombolytic agents, 1376 
compared with alteplase and heparin, 1352-1353 
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contraindications to, 1344 
mechanism of action, 1373 
prehospital use of, 1338 
in prevention of thrombotic complications of
atheroselerosis, 1374 
recmnmcndations for, 1344 
risk of hemorrhagic stroke with, 1734 
for secondary prevention, long-term use of, 
1396-1397, 1398 
side effects and dosage, 1374 
suppositories. 1344 
use of 
after first 24 hours, 1334 
during first 24 hours, 1334 
Asystolc. See Ventricular asystole 
Atenolol, 1363, 1381, 1382 
for vcntricular fibrillatkm prophylaxis, 1365 
Atherosclerosis 
nitrate effects on, 1372 
progression of, repeat corona U artery bypass 
graft surgery for, 1369 
in saphenous vein grafts, 1395 
thrumbotic complications of, prevention of, 
aspirin in, 1373-1374 
ATRAMI (Autonomic Tone and Reflexes after 
Myocardial Infarction), 1391 
Atrial fibrillation 
incidence of, 1363 
in right ventricular infarction and dysfunction, 
1360, 1361 
in right ventricular ischemia, 1361 
transient, 1364 
treatment of, 1335 
recommendations for, 1363-1364 
Atrial pressure, in right vcntricular isehemia, 1360 
Atriovcntricular (AV) block 
atropine for, 1344 
pacing for. 1367 
prognosis of, 1366 
treatment of, 1335 
Atrioventricular (AV) synchrony, 1368 
in right ventricular ischemia/infarction, 1361, 
136lt 
Atropine, 1334, 1335, i356 
for atrioventricular block, sinus bradycardia, or 
ventricular asystole, 1344 
for bradyarrhythmias and heart block, 1366-1367 
recommendations, 1344, 1345 
side effects of, 1345 
Autonomic Tone and Refllexes after Myocardial 
lnfaretion. See ATRAMI 
B 
Balloon flotation right-heart catheter monitoring, 
1361-1362 
Barorcflex 
sensitivity, sudden cardiac death risk and, 1391 
stimulation, abnormal, 1335 
Bed rest, 1354 
duration of, 1354 
/3-adrenergic blocking agents, 1335, 1337, 1352, 
1353, 1380, 1383. See also specific agent 
adverse ffects of, 1397 
for atrial fibrillation, 1363, 1364 
contraindications to, 1381, 1382 
description of, 1381 
diltiazcm use with, I384 
long-term therapy, fi~r secondary, prevention, 
1397-1398 
nitroglycerin use with, 1372 
recommendations for early therapy, 1381-1382 
usc 
after first 24 hours, 1335 
during first 24 hours, 1334 
for ventricular fibrillation prophylaxis, 1365 
for ventricular tachycardia, 1365 
Beta carotene, 1398 
Bezold-Jarish reflex, 1366 
Bile acid sequestrants, 1396 
Blood flow 
collateral, 1359 
effect of increased perfusion pressure on, 1362- 
1363 
nitrate effects on, 1372 
PTCA effects on, 1392 
compared with thrombolytic therapy, 1350 
reestablishment of, with thrombolytic therapy, 
1374, 1375 
Blood pressure, 1333, 1338. See also Hypertension: 
Hypotension 
effect of caffeine on, 1355 
in left ventricular dysfunction, 1359 
monitoring of, in hospital, 1354 
Blood specimens, 1357 
Bradyarrhythmias 
background, epidemiolog),, and importance of, 
1366 
prognosis of, 1366 
treatment of, 1366-1368 
Bradycardia, 1343. See also Sinus bradycardia 
nitroglycerin-related, 1372 
Breathing difficulties, 1338 
Bretylium 
dosage for, 1381 
pharmacology, 138l 
for ventricular fibrillation, 1365 
Bronchoplastic disease, 1383 
Bundle branch block (BBB), 1335, 1366, 1377 
diagnostic and treatment measures for, 1350t 
carly angiography in, 1351 
left, I334 
symptoms of, 1333 
management of, 1345f, 1340 
pacing for, 1367, 1368 
thrombolytic therapy fur, 1346, 1347, 1347f 
C 
Caffeine intake, 1355 
Calcium channel blocking agents. 1353, 138l, 1399. 
See also specific agent 
for atrial fibrillation, 1364 
diltiazem, 1363, 1383, 1384 
during first 24 hours, 1334 
nifedipine, 1383 
recommendations, 1383 
for secondary prevention, 1398 
summary of, 1384 
verapamil, 1363, 1383-1384 
CAMIAT (Canadian Amiodarone Myocardial 
Infarction Arrhythmia Trial), 1400 
Canadian Amiodarone Myocardial Infarction 
Arrhythmia Trial. See CAMIAT 
Captopril, 1373, 1382, 1383 
for secondary prevention, 1397 
Cardiac arrest 
mortality rates for, 1369 
prchospital treatment of, survival rate related to, 
1338, 1339 
Cardiac catheterization, 1338, 1340, 1386 
in mechanical defects, 1370 
in non-ST-segment elevation cohort. 1353 
following thrombolytic therapy, 1393 
Cardiac events, recurrence of, 1337, 1400 
Cardiac output 
in left ventricular dysfunction, 1359 
low, 1344, 1385 
in right ventricular ischemia/infarction, 1361 
thermodilutinn, 1370 
Cardiac rehabilitation, 1335, 1399-1400 
exercise testing and. 1387 
Cardiac rupture 
recurrent chest pain from, 1359 
risk factors for, 1359 
Cardiac tamponade, 1358, 1359 
Cardiac transplantation, 1371 
Cardiogenic shock. See Shock, cardiogenic 
Cardiologists, interventional 
corridor of outcomes and, 1350 
PTCA performed by, 1350 
Cardiopulmonary resuscitation (CPR), 1337, 1356 
patients undergoing, coronary, artery bypass graft 
surgery, for, 1369 
Cardiovascular disease 
antioxidants for, 1398 
after bed rest, 1354 
magnesium and, 1384 
Cardioversion, 1335 
for atrial fibrillation, 1363 
for ventricular tachycardia, 1364 
CARE (Cholesterol and Recurrent Events) trial, 
1395 
CAST substudy, 1391 
Catecholamines, inotropic agents, 1385 
Catheter, 1335 
balloon flotation, 1361-1362, 1370 
central, 1362 
intra-arterial, 1362 
Catheterization. See Cardiac catheterization 
Chest discomfort, 1338. See also Angina pectoris 
checklist for, 1339, 1339t 
ischcmic-type, 1338-1339, 1340 
sympathetic drive and, 1355 
referral of, 1338 
treatment of, 1335 
Cholesterol. See Lipids, Lipoprotein 
Cholesterol and Recurrent Events trial. See CARE 
trial 
Chronic obstructive airway disease. 1343 
Cimetidine, 1356. 1374 
Circulatory support devices, for failing heart, 1371 
Class I conditions, 1336 
angiotensin-converting chime inhibitors in, 
1382 
atrial fibrillation in, 1363 
atropine for, 1344, 1366 
balloon flotation right-heart catheter monitoring 
in. 1361 
/3-adrcnergic blocking agents for, 1381 
emergency or urgent coronary artery bypass graft 
surgery for, 1351 
hcparin in, 1377 
hospital management of, early, general 
measures, 1354 
initial recognition and management i  
emergency department, 1340 
intra-aortic balloon counterpulsation in, 1362 
intra-arterial pressure monitoring in, 1362 
invasive valuation of, 1392 
management of recurrent chest pain in, 1358 
noninvasive valuation of. 1386 
nun-ST segment elevation in, risk stratification 
and management, 1352 
oxygen, nitroglycerin, and aspirin for, 1342, 1343 
pacing for, 1367. 1368 
prehospital issues, 1337 
primary, pcrcutaneous transluminal coronary 
angioplasty in, 1350 
secondary prevention i  
/3-adrenoceptor blocking agents fnr, 1397 
long-term anticoagulation, 1398 
thrombulytic therapy for, 1346 
ventricular tachycardia/fibrillation in, 1364 
1422 RYAN ET AL. JACC Vol. 28, No. 5 
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION November 1, 1996:1328-428 
Class II conditions, 1336 
Class IIa conditions, 1336 
angiotensin-converting e zyme inhibitors in, 
1382 
atrial fibrillation in, 1363 
atropine for, 1344 
balloon flotation right-heart catheter monitoring 
in, 1361 
calcium channel blockers for, 1383 
early angiography in, 1351 
emergency or urgent coronary- artery bypass graft 
surgery for, 1351 
heparin in, 1377 
intra-aortic balloon counterpulsation i , 1362 
intra-arterial pressure monitoring in, 1362 
invasive valuation of, 1392 
magnesium for, 1384 
management of lipids in, 1395 
management of recurrent chest pain in, 1358 
noninvasive evaluation of, 1386 
non ST segment elevation in, risk stratification 
and management, 1352 
oxygen, nitroglycerin, and aspirin for, 1342. 1343 
pacing for, 1367. 1368 
prehospital issues, 1337 
primary percutaneous transluminal coronary 
angioplasty in, 1350 
secondary, prevention in 
/3-adrenoceptor blocking agents for, 1397 
estrogen replacement therapy, 1399 
long-term anticoagulation, 1398 
thrombolytic therapy for, 1346 
ventricular tachycardia/fibrillation n. 1364 
Class lib conditions, 1336 
angiotensin-converting e ~'me inhibitors in. 
1382 
atropine for, 1344 
/?-adrenergic blocking agents for. 1381 
calcium channel blockers for, 1383 
early angiography in, 1351 
emergency or urgent coronary artery bypass graft 
surgery for, 1351 
heparin in, 1377 
hospital management of, early, general 
measures, 1354 
intra-aortic balloon counterpulsation i , 1362 
intra-arterial pressure monitoring in, 1362 
invasive valuation oL 1392 
magnesium for, 1384 
management of lipids in, 1395 
management of recurrent chest pain in, 1358 
non-ST segment elevation in, risk stratification 
and management, 1352 
oxygen, nitroglycerin, and aspirin for, 1342. 1343. 
1344 
pacing for, 1367, 1368 
prehospital issues, 1337 
primary percutaneous transluminal coronary 
angioplasty in, 1350 
secondary prevention in, long-term 
anticoagulation, 1398 
thrombolytic therapy for, 1346, 1347 
ventricular arrhythmia ssessment, 1391 
ventricular tachycardia/fibrillation n, 1364 
Class III conditions, 1336 
atropine for, 1344, 1366 
balloon flotation right-heart catheter monitoring 
in, 1361 
/3-adrenergic blocking agents for, 1381 
calcium channel blockers for. 1383 
early angiography in, 1351 
emergency or urgent coronary artery bypass graft 
surgery for, 1351 
heparin in, 1377-1378 
hospital management of, early, general 
measures, 1354 
intra-arterial pressure monitoring in, 1362 
invasive valuation of, 1392, 1393 
noninvasive evaluation of, 1386 
oxygen, nitroglycerin, and aspirin for, 1343 
pacing for, 1367, 1368 
secondary prevention in,/3-adrenoceptor 
blocking agents for, 1397 
thrombolytic therapy for, 1347 
ventricular tachycardia/fibrillation n, 1364 
Clinical end-point, effect of intra-aortic balloon 
pumping on, 1363 
Clinical variables 
assessment of, 1357, 1357f 
mortality risk and, 1356, 1357f 
Clonidine, 1396 
Coagulation, heparin effects on, 1378 
Coagulation cascade, activation of, 1377 
Coagulation system, breakdown of, 1378 
Collateral blood flow, lack of, 1359 
Commode privileges, 1354, 1355 
Complications, freedom from, 1356 
Computed tomography, single-photon emission 
(SPECT), 1388 
Computer algorithms, 1354 
Computer-aided diagnostic aids, 1340 
Conduction 
delay, intraventricular, 1366 
disturbances, 1368 
Confidence interval, 1339 
Congestive heart failure (CHF), 1368, 1380 
ACE inhibitors for, 1334, 1382 
incidence of, magnesium effects on, 1384 
management of, 1335 
in hospital, 1359-1362 
mechanical support for, 1371 
nitrates in, 1372 
in pericarditis, 1358 
CONSENSUS (Cooperative New Scandinavian 
Enalapril Survival II) Study, 1382 
Contractility, 1385 
Cooperative New Scandinavian Enalapril Survival 
II Study. See CONSENSUS study 
Coronary artery bypass graft (CABG) surgery, 1337 
clinical situations leading to. 1368-1370 
emergency, 1333, 1350, 1351 
recommendations for, 1351-1352 
in left ventricular dysfunction, 1359 
minimum operative caseload, 1371 
myocardial infarction during, 1395 
use rates, 1377 
in ventricular septal defect, 1371 
volume of, relation to outcome, 1371 
Coronary artery disease 
blood lipid profile in, 1396 
myocardial infarction incidence related to, 1395 
Coronary artery patency, thrombolytic therapy and, 
1392, 1393 
Coronary care unit (CCU) 
admission to, 1340 
alternatives to, 1356 
electrocardiography in, 1354 
intra-arterial pressure monitoring in, 1362 
length of stay in, reduction of, 1356 
temporary pacemaker care in, 1368 
transfer from, 1357 
Coronary flow. See Blood flow 
Coronary heart disease. See Coronary artery 
disease 
Coronary, occlusion, 136(I 
revascularization in, 1353 
thrombus in, 1376 
total, 1352 
treatment of, 135%1360 
Coronary perfusion 
effect of heparin on. 1378 
in right ventricular infarction and dysfunction, 
1360 
"Coronary precautions," 1354 
Coronary reocclusion, 1363 
"Corridor of outcomes," 1350 
Corticosteroids, for chest discomfort, 1358 
Costs 
PTCA compared with thrombolytic therapy, 
1351 
reduction of, 1356, 1357 
Counterpulsation, i tra-aortic balloon 
in left ventricular dysfunction, 1359 
recommendations for, 1362-1363 
Countershock, for ventricular fibrillation, 1335 
Couplets, 1364 
Creatine ldnase (CK), 1334, 1356, 1395 
Creatine kinase-MB (CK-MB), 1340, 1341 
in pericarditis, 1358 
in reinfarction, 1358 
D 
DANAMI (Danish Acute Myocardial Infarction) 
Trial, 1394 
Danish Acute Myocardial Infarction Trial. See 
DANAMI Trial 
Defibrillation, defibrillator, 1334, 1337, 1356 
automatic external (AED), 1339 
prehospital, 1338-1339 
for ventricular fibrillation, 1365 
Delirium, 1356 
Demographic variables, assessment of, 1357, 1357f 
Depression, decrease in, 1356 
Desirudin, 1380 
Dextrose, 1381 
Diabetes, 1348 
thrombolytic therapy and, 1346 
Diagnosis, 1357 
time required for, 1338 
Diaphoresis, 1338 
Diastole,/3-adrenoreceptor effects on, 1381 
Diastolic dysfunction, right ventricular, 1360 
Diazepam, 1356 
Diet, 1335 
for management of lipids, 1395 
DIG. See Digitalis Investigator Group 
Digitalis, 1335, 1385 
in atrial fibrillation, 1363 
pharmacology, 1386 
Digitalis Investigator Group (DIG), 1386 
Digoxin, 1363 
Dihydropyridines, use, during first 24 hours, 1334 
Diltiazem, 1383 
for atrial fibrillation, 1363 
contraindications to, 1383 
pharmacology, 1384 
use, during first 24 hours, 1334 
Dipyridamole, 1344, 1386, 1388, 1396 
Discharge from hospital, preparation for, 1335 
invasive valuation, 1392-1395 
noninvasive valuation of low risk patients, 
1386-1391 
secondary prevention, 1395-1399 
Diuretics, diuresis, 1335, 1359 
in right ventricular ischemia/infarction, 1361 
Dobutamine, 1385t, 1388, 1389 
Doom, impending, feeling of, 1338 
Dopamine, 1385, 1385t 
for hypotension, 1385 
in left ventricular dysfunction, 1359 
Dressier syndrome, 1358 
Driving, 1401 
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DUCCS-1 study, 1378 
Duteplase, 1376 
Dyspnea, 1387 
E 
Echocardiography, echocardiogram 
in cardiac rupture, 1359 
in emergency department, 1346 
exercise, 1335. 1390 
for discharge from hospital, 1386 
in pseudoaneurysm, 1359 
resting, abnormalities in, 1386n 
in right ventricular ischemia, 1360, 1361 
role in preparation for discharge from hospital. 
1388-1389 
two-dimensional, 1340 
Ectopy. See Ventricular ectopy 
Education, 1338, 1399 
patient, 1333 
effect on emotional distress, 1355 
Ejection fraction, 1389, 1391, 1392 
ACE inhibitor effects on, 1334, 1397 
in pericarditis, 1358 
Elderly. See also Age 
non-diagnostic ECG changes in, 1352 
non-Q wave myocardial infarction in, 1352 
percutaneous transluminal coronary angioplasty 
in mortality rates, compared with 
thrombolytic therapy, 1350 
reperfusion therapy in, I352 
symptoms of acute myocardial infarction in. 1340 
thrombolytic therapy for, 1346 
effcct on mortality rates, 1348 
risk of stroke and, 1349 
Electric shock, for ventricular 
tachycardia/ventricular fibrillation, 1364, 
1365 
Electrical instability, 1335 
"Electrical storm," 1365. 1381 
Electrocardiography, electrocardiogram (ECG), 
1340. See also Holter monitoring; specific 
segment; specific wave 
in CCU, 1354 
effect of thrombolytic therapy on, 1345 
exercise, 1387 
interpretation of, errors in, 1340 
nondiagnostic changes, 1340, 1352 
effect of thrombolytic therapy in, 1353 
mortality rates related to, 1353 
normal, mortality rates rates in, 1352 
prehospital, 1339 
in recurrent chest pain, 1358 
in right ventricular ischemia, 1360 
signal-avcraged, for ventricular arrhythmia 
assessment, 1391 
Electrolyte disturbances, in ventricular fibrillation, 
1364 
Electrophysiologic mechanisms, in myocardial 
infarction, 1364 
Embolic stroke, 1378 
Embolization, in atrial fibrillation, 1363 
Emergency department (ED), initial recognition 
and management of acute myocardial 
infarction in, 1333-1334, 1349, 134% 1350t 
atropine in, 1344-1345 
detection/quantitation and risk assessment, 
1340-1342f 
noninvasive imaging, 1345, 1346 
recommendation, 134(I 
risk stratification and management of ST- 
segment elevation/bundle branch block 
cohort, 1345, 13451, 1346 
routine measures (oxygen, nitroglycerin, aspirin), 
1342-1344 
thrombolysis, 1346-1349 
Emergency medical services (EMS) system, 1338- 
1339 
capabilities of, 1338-1339 
early access to, 1338-1339 
Emergency medical system personnel, 1333, 1339 
Emergency medical technicians (EMTs), work of, 
healthcare settings for, 1338-1339 
EMIAT (European Myocardial Infarction 
Amiodarone Trial), 1400 
Enalapril, 1382, 1383 
for secondary prevention, 1397 
Enalaprilat, 1383 
Endothelium-derived relaxing factor (EDRF), nitric 
oxide, 1372 
Epinephrine, 1334 
for ventricular fibrillation, 1365 
Estrogen replacement therapy (ERT), myocardial 
infarction and, 1399 
European Cooperative Study Group VI triak 1394 
European Myocardial Infarction Amiodarone Trial. 
See EMIAT 
Exercise, I335 
Exercise testing. See also under Echocardiography 
for discharge from hospital, 1335, 1390 
echocardiography, 1387 
low-level, 1387 
myocardial perfusion imaging, 1387, 1388 
optimum time for performing, 1387 
symptom-limiting, 1387 
myocardial perfusion imaging, 1387, 1388 
F 
Factor V, 1378 
Factor VII, 1378 
Factor X, 1378 
Factor Xa, 1379 
Family members, care by, 1355-1356 
Fascicular block, pacing for, 1368 
Fibrates, 1396 
Fibrillation. See Atrial fibrillation; Ventricular 
fibrillation 
Fibrin, 1377, 1393 
Fibrin-specificity of thrombolytic agents, 1375 
Fibrioogen, 1377 
Fibrinogen degradation products, 1378 
Fibrinolytic therapy. See Thrombolytic therapy 
First International Study of Infarct Survival, 1382 
First responders, 1338-1339 
Fluid, 1354. See also Water 
Free wall rupture, left ventricular, 1359 
Furosemide, 1335, 1359 
G 
Gastric side effects, of aspirin, 1374 
Gemfibrozil, 1395, 1396 
Gender, 1348 
GISS1 (Gruppo Italiano per Io Studio della 
Streptochinasi nell'infarto Miocardico) 
study, 1352 
GISSI-2, 1376, 1378 
GISSI-3 trial, 1373, 1382, 1383 
Global Utilization of Streptokinase and TPA for 
Occluded Arteries trial. See GUSTO trial 
Gruppo Italiano per 1o Studio della Streptochinasi 
nell'infarto Miocardico study. See GISSI 
study 
GUSTO (Global Utilization of Streptokinase and 
TPA for Occluded Arteries) trial, 1334, 
1363, 1369, 1376 
GUSTO-I, 1378 
GUSTO-IIb, 1351, 1380 
H 
Hand perfusion, 1362 
Headache, nitroglycerin-related, 1372 
Healthcare providers, local, involvement of, 1339 
Heart block. See also Atrioventricular block; 
Bundle branch block 
background, epidemiology, and importance of, 
1366 
prognosis of, 1366 
risk factors fnr, 1366 
treatment of, 1366-1368 
Heart failure. See Congestive heart failure 
Heart rate, 1338, 1385 
low, thrombolytic therapy and, 1346 
nitrate effects on, 1372 
variability, 1391 
Hclsinki Primary Prevention Trial, 1396 
Hemodynamic compromise 
in atrial fibrillation, 1363 
emergency or urgent coronary artery bypass graft 
surgery for, 1351 
in left ventricular dysfunction, 1359 
in right ventricular infarction and dysfunction, 
1360 
Hemodynamic monitoring 
balloon flotation right-heart catheter monitoring, 
1361-1362 
intra-aortic balloon counterpulsation, 1362-1363 
intra-arterial pressure monitoring, 1362 
Hemorrhage, 1373 
intracranial (ICH), 1380 
intraplaque, 1374 
risk of. aspirin and, 1374 
thrombolytic therapy-related, 1375 
intracranial (ICH), 1333, 1349, 1376 
Heparin, 1334, 1353, 1358 
as antithrombotic agent, 137%1380 
for atrial fibrillation, 1363 
combined with thrombolytic agents, 1376 
compared with alteplase and aspirin, 1352-1353 
discontinuation of. 1379 
dosing, in thrombolytic therapy, 1379 
duration of therapy, 1379 
interaction with nitroglycerin, 1373 
low molecular weight, 1380 
pharmacology, 1378 
recommendations, 1377-1380 
unfractionated, 1379 
use 
after first 24 hours, 1334, 1335 
with PTCA, 1334 
after thrombolytic therapy, 1334 
Heparin-ATllI complex, 1378 
High risk patient 
in hospital identification and treatment of 
for bradyarrhythmias nd heart block, 1366- 
1368 
for heart failure and low-output syndrome, 
1359-1362 
intra-aortic balloon counterpulsation, 1362- 
1363 
intra-arterial pressure monitoring, 1362 
for recurrent chest discomfort, 1358-1359 
for rhythm disturbances, 1363-1368. See also 
Rhythm disturbances 
surgical interventions, 1368-1370 
for ventricular tachycardia/ventricular 
fibrillation, 1364-1366 
prehospital identification of, 1338. 1339 
Hirudin, 1379, 1380 
History, i340 
HmG CoA reductase drugs, I395n, 1396 
Holter monitoring, 1399 
for ischemia, 1390-1391 
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for ventricular arrhythmia ssessment, 1391 
Home exercise training programs, 1400 
Hospital, nearest, location of, 1338 
Hospital management of acute myocardial 
infarction. See also Discharge from hospital 
case selection concerns, 1371 
early, general measures, 1354-1356 
first 24 hours, 1334 
after first 24 hours, 1334-1335 
identification and treatment of patient at high 
risk, 1358-1370 
identification and treatment of patient at low 
risk, 1356-1357 
of mechanical defects after acute myocardial 
infarction, 1370t, 1370-1371 
minimum operative caseload, 1371 
relation between volume of surgery, and 
outcome, 1371 
transplantation after acute myocardial infarction. 
1371 
visiting rules, 1356 
Hospital stay, reduction of, 1355, 1356 
Hypercholesterolemia, 1395 
Hypertension 
cardiac rupture in, 1359 
nitrate effects on, 1372 
thrombolytic therapy and, 1346, 1347. 1349 
Hypertriglyceridemia, 1396 
Hypokalemia, 1384 
ventricular fibrillation risk and, 1365 
Hypoperfusion, peripheral, 1344 
Hypotension, 1339, 1348, 1354, 1385 
atropine for, 1344 
early sustained, absence of, 1356 
exertional, 1387 
intra-arterial pressure monitoring in, 1362 
morphine-induced, 1355 
nitroglycerin-related, 1343, 1361, 1372 
in sinus bradyeardia, 1366, 1367 
thrombolytic therapy and, 1346 
treatment of, 1335 
Hypoxemia, 1372 
correction of, 1343, 1344 
I 
Ibuprofen, for chest discomfort, 1358 
Identification of myocardial infarction, prehospital, 
1333 
Idiovcntricular rhythm, accelerated, 1364. 1365 
Incomplete Infarction Trial of European Research 
Collaborators Evaluating Prognosis Post 
Thrombolysis trial. See INTERCEPT trial 
Indomethacin, for chest discomfort, 1358 
Infarct size 
measurement of, 1390 
in pericarditis, 1358 
Inferior myocardial infarction 
atropine for, 1344 
right ventricular infarction accompanying, 1360 
use of nitrates in, 1372 
lnotropic agents, 1335, 1362. 1385-1386 
classification of, 1385, 1385t 
in right ventricular ischemia/infarction. 1361 
INTERCEPT trial (Incomplete Infarction Trial of 
European Research Collaborators 
Evaluating Prognosis Post Thrombolysis), 
1384 
Internal jugular vein, for transvenous pacing, 1368 
International Normalized Ratio (INR). for 
anticoagulants, 1398 
International Study of Infarct Survival. See under 
ISIS 
Interventional therapy, in non-ST-segment 
elevation cohort, 1352-1354 
Intra-aortic balloon pump (IABP), 1370 
for failing heart, 1371 
for ventricular tachyarrhythmias, 1369 
Intra-arterial pressure monitoring, 
recommendations for, 1362 
Intravascular volume, inadequate, 1361 
Invasive valuation, for preparation for discharge 
from hospital, 1392-1395 
lschemia, 1335, 1383. See also Myocardial ischemia 
exercise-induced, after thrombolytic therapy, 
1394 
incidence of, magnesium effects on, 1384 
management of, in hospital, 1358-1359 
persistent or recurrent, 1380 
coronary artery bypass graft surgery for, 1369 
emergency or urgent coronary artery bypass 
graft surgery for, 1351 
intra-aortic balloon counterpulsation i , 1362 
1363 
PTCA for, compared with thrombolytic 
therapy, 1351 
revascularization for, 1350 
right ventricular, 1360. See also Right ventricular 
infarction and dysfunction 
management of, 1361, 1361t 
treatment of, 1345 
unstable, 1362 
ISIS-2 (Second International Study of Infarct 
Survival), 1344, 1352, 1375 
ISIS-3, 1376, 1378 
ISIS-4, 1373, 1382, 1383, 1384-1385 
lsoproterenol, 1385. 1385t 
Isosorbide dinitrate (ISDN), pharmacokinetics and 
dosage, 1372 
Isosorbide mononitrate (ISMN), 1373 
pharmacokinetics and dosage, 1372 
L 
Laboratory tests, for confirmation of myocardial 
infarction, 1340, 1341. See also specific 
procedure 
Late Assessment of Thrombolytic Efficacy Trial. 
See LATE Trial 
LATE (Late Assessment of Thrombolytic Etficacy) 
Trial, 1347, 1353 
Late potentials, 1335 
sudden cardiac death and, 1391 
Left subclavian vein, for transvenous pacing, 1368 
Left ventricular dysfunction, 1391 
coronary artery bypass graft surgery for, 1369, 
1370 
management of, 1359-1360 
in right ventricular ischemia/infarction, 1361 
Left ventricular function 
assessment of, fur discharge from hospital, 1389 
effect of intra-aortic balloon pumping on, 1363 
after thrombolytic therapy, 1393-1394 
Left ventricular remodeling, nitroglycerin effects 
on, 1373 
Leg elevation, 1344 
Licenses, 1357 
Lidocaine, 1335, 1356 
dosage of, 1381 
pharmacology of, 1381 
for ventricular fibrillation, 1365 
for prophylaxis, 1365 
for ventricular tachycardia, 1364, 1365 
Limb perfusion, 1362 
LIMIT-2 (Second Leicester Intravenous 
Magnesium Intervention Trial) trial, 1384 
Lipid(s), management of, for secondary prevention, 
1395-1396 
Lipoprotein 
high-density (HDL). 1395. 1396 
low-densiW (LDL), 1395 
reduction of, 1335 
Lisinopril, combined with nitrates, 1373 
Loading conditions, changes in, during Valsalva 
maneuver, 1354 
Long-term management, 1400 
cardiac rehabilitation, 1400 
return to prior level of activity, 1400t, 1400-1401 
Low-risk patients 
identification and treatment of, in hospital, 
1356-1357 
noninvasive evaluation of. See Noninvasive 
evaluation 
M 
MAGIC (Magnesium in Coronary. Disease) trial, 
1385 
Magnesium, magnesium sulfate 
background, 1384, 1385 
recommendations, 1384 
repletion of, 1365 
use, after first 24 hours, 1334 
Magnesium in Coronary' Disease trial. See MAGIC 
trial 
MDPIT (Multicenter Diltiazem Postinfarction 
Trial), 1384 
Mechanical defects, after acute myocardial 
infarction, management of
acute mitral valve regurgitation, 1370-1371 
diagnosis, 1370t, 1370-1371 
left ventricular aneurysm, 1371 
left ventricular free wall rupture, 1371 
mechanical support of failing heart, 1371 
surgery for, 1368 
Medical care, seeking of, timing for, 1338 
Medications. See Pharmacotherapy 
Medroxy-progesterone, 1399 
Meperidine, 1333, 1356 
MET level, 1400t, 1401 
Meloprolol, 1363, 1381 
for secondary prevention, 1397 
for ventricnlar fibrillation prophylaxis, 1365 
Metoprolol in Acute Myocardial Infarction trial. 
See MIAMI trial 
Mexiletine, 1356 
MIAMI (Metoprolol in Acute Myocardial 
Infarction) trial, 1382 
Milrinone, 1385, 13851, 1386 
Mitral valve 
regurgitation, postinfarction, management of, 
1371 
emergency or urgent coronary artery bypass 
graft surgery for, 1351 
replacement, 1370 
Morphine, morphine sulfate, 1333, 1343 
administration, in hospital, 1355-1356 
adverse ffects of, 1355 
atropine combined with, 1344 
side effects of, 1344 
Mortality. See also Sudden cardiac death 
predictors of, 1391 
risks of, 1356, 1357f 
Mortality rate, in acute myocardial infarction, 1337, 
1350 
angiotensin-converting e zyme inhibitors effect 
on, 1382-1383 
aspirin effects on, 1344, 1396 
atenolol effects on, 1382 
cardiac arrest-related, 1369 
in cardiogenic shock, 1359-1360 
conduction disturbances and, 1368 
coronary artery bypass graft surgery-related, 
1369 
digitalis effects on, 1386 
JACC Vol. 28, No. 5 RYAN ET AL. 1425 
November 1, 1996:1328 428 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
diltiazem effects on, 1384 
exercise testing and, 1387 
heart block and intraventricular conduction 
delay-related, 1366 
heparin effects on, 1378 
hospital staffing related to, 1357 
left ventricular function and, 1389 
magnesium effects on, 1384 
nifedipine effects on, 1383 
nitrate effects on, 1373 
in nondiagnostic ECG changes, 1353 
operative, in ventricular septal defect, 1371 
periprocedural myocardial infarction-related, 
1395 
prehospital, 1333 
PTCA and, compared with thrombolytic therapy, 
1350, 1351 
reduction in, 1337, 1387 
simvastatin effects on, 1395 
ST-segment elevation-related, 1340 
in survivors of MI, predictors oL 1393 
thrombolytic therapy effects on, 1333, 1346, 
1347L 1348, 1348t, 1375, 1376 
time factor in, 1334 
in ventricular fibrillation. 1365 
verapamil effects on, 1384 
volume of surgery and, 1371 
Multicenter Diltiazem Postinfarction Trial. See 
MDPIT 
Murmur, 1370 
Myocardial damage, minimizing of, 1354 
Myocardial hibernation, assessment of, 1388-1389 
Myocardial infarction (MI) 
complications of, recognition and management 
of, 1335 
coronary artery, bypass graft surgery, for, elective, 
1369 
diagnosis of, 1340 
timing for. 1356 
evolving, coronary artery bypass graft surgery 
for, 1369 
exclusion oL 1356, 1357 
incidence of, 1333, 1337 
reduction of. See also Secondary prevention 
management of
ACC/AHA guidelines for, 1332 
in emergency department, 1333-1334 
hospital. See Hospital management 
long-term, 1335 
prehospital issues, 1333 
pathophysiology of, 1376 
patients. See Patients 
symptoms of, 1333. 1338 
time-dependent process of, 1341 
true, identification of patients with, 1340 
Myocardial ischemia 
after first 24 hours, 1334 
Holter monitoring for, 1390-1391 
nitroglycerin-related, 1343 
reduction of. 1364 
treatment of, 1335 
Myocardial necrosis 
biochemical markers of, assays for, 1341 
serum markers of. 1346 
Myocardial perfusion imaging, 1390 
exercise, 1387, 1388 
for infarct size measurement, 1389-1390 
Myocardial protection, in acutely injured heart, 
coronary artery bypass graft surgery' for 
1370 
Myocardial viability,, assessment of, 1389 
Myocyte, necrosis, serum cardiac markers of, 1334 
Myoglobin, 1341, 1342t. i356 
N 
Naloxone, 1355 
NAMIS (Nifedipine Angina Myocardial Infarction 
Study), 1383 
Narcotics, 1334 
Nasal prongs, 1343 
National Cholesterol Education Panel, 1396 
National Heart, Lung, and Blood Institute 
(NHLBI), 1337, 1385 
National Heart Attack Alert Program (NHAAP), 
I337 
National Registry of Myocardial Infarction, 1376 
Nausea and vomiting, 1344 
Neck veins, in right ventricular ischemia, 1360. 
1361 
Necrosis. See Myocardial necrosis 
NHLBI. See National Heart, Lung, and Blood 
Institute 
Niacin, 1395, I395n 
Nicotine gum and patches, 1396 
Nicotine withdrawal, 1356 
Nicotinic acid, 1396 
Nifedipine, 1334 
contraindications to, 1383 
pharmacology, 1383 
Nifedipine Angina Myocardial Infarction Study. See 
NAMIS 
911 system, 1338-1339 
Nitrates, 1353, 1380 
clinical trials of, 1373 
in right ventricular ischemia/infarction. 1361 
tolerance to, 1372 
Nitric oxide, 1372 
Nitroglycerin, 1333, 1334, 1335, 1343, 1354, 1362 
clinical trials of, 1373 
contraindications to, 1343 
intravenous, 1372 
recommendations for, 1343 
for left ventricular dysfunction, 1359 
limitations and adverse ffects, 1343, 1372-1373 
mechanism of action, 1372 
pharmacokinetics and dosage, 1372 
prehospital use o£ 1338 
sublingual, 1343 
titration of, 1372 
transdermal, 1343 
Noninvasive valuation 
in emergency department, 1346 
of low risk patient. See also Echocardiography 
ambulatory electrocardiographic monitoring 
for ischemia, 1390-1391 
assessment ofventricular arrhythmia, 1391 
of left ventricular function, 1389 
measurement of infarct size, 1389-1390 
radionuclide testing for diagnosis of acute 
myocardial infarction, 1389 
recommendations, 1386 
role of echocardiography, 1388-1389 
role of exercise testing, 1386-1388. See also 
Exercise testing 
positive predictive value, 13911 
Non-Q wave myocardial infarction, 1345, 1354 
heparin in, 1380 
interventional therapy for, 1353 
risk stratification and management in, 1352 
Norepinephrine, 1380, 1385, 1385t 
for hypotension, 1385 
in left ventricular dysfunction, 1359 
No~'egian Nifedipine Multicenter Trial, 1383 
O 
Occlusion. See Coronary occlusion 
Open infarct-related artery., 1391 
Opiate therapy, 1344 
OSIRIS study, 1378 
Outcome, relation to volume of surgery, 1371 
Oximeto,, 1354 
Oxygen 
administration, in emergency department, 1342, 
1344 
consumption, effect of increased perfusion 
pressure on, 1362-1363 
demand and supply, 1354, 1355 
/3-adrenoreceptor effects on, 1381 
myocardial. 1372 
in right ventricular infarction and dysfunction, 
1360 
saturation, I370 
monitoring of, 1343, 1354. See also Oximetry 
P 
Pacemaker, 1356 
Pacing, 1334 
AV (dual chamber), 1368 
for bradyarrhythmias and heart block, 1366, 
1367-1368 
after first 24 hours, 1335 
permanent, 1368 
in right ventricular ischemia/infarction, 1361 
transcutaneous, 1367 
transvenous, temporary., 1367-1368 
ventricular (single chamber), 1368 
Pain. See also Angina pectoris; Chest discomfort of 
acute myocardial infarction, 1343 
PAMI (Primary Angioplasty in Myocardial 
Infarction) investigators, 1350 
PAMI-II study, 1400 
Parasympathetic one, influence on heart, 1391 
Patency, 1334 
Patient(s) 
classification of, 1337 
with myocardial infarction, differences in, 1336 
Patient delay, interventions to minimize, 1338 
Percutancous transluminal coronary angioplasty 
(PTCA). See Angioplasty, percutaneous 
transluminal coronary. 
Perfusion. See Coronary. perfusion; Myocardial 
perfusion imaging 
Pericardial tamponade, 1370 
Pericardiocentesis, 1359 
Periearditis 
in atrial fibrillation, 1363 
chest pain from, 1335 
focal, 1358 
management of, in hospital, 1358-1359 
Personnel. for cost reduction, 1357 
Pharmacothera W 
for management of lipids, 1395-1396 
for nicotine withdrawal, 1356 
in non-ST-segment elevation cohort, 1353 
prehospital, 1338 
rationale arid approach to, 1372 
angiotensin-converting e zyme inhibitors, 
1382-1383. See also Angiotensin-converting 
cnzyme inhibitors 
antiarrhythmics, 1380-1382. See also 
Antiarrhythmic agents 
antithrombotics/anticoagulants, i37%1380. See 
also Antithrombotics/Anticoagulants 
aspirin and other platelet active drugs, 1373- 
1374. See also Aspirin; Platelet-active drugs 
/3-adrenoceptor blocking agents, 1381-1382. 
See also/3-adrenergic blocking agents 
calcium channel blockers, 1383-1384. See also 
Calcium channel blockers 
inotropic agents, 1385t, 1385-1386. See also 
Inotropic agents 
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magnesium, 1384, 1385. See also Magnesium 
nitroglycerin, 1372-1373. See also 
Nitroglycerin 
thrombolytic therapy, 1374-1377. See also 
Thrombolytic therapy 
Phosphodiesterase inhibitors, 1385 
Physical activity, 1334 
limiting of, 1354 
Plaque 
fissuring or rupture of, 1374, 1377 
rupture, 1393 
Plasmin, 1375 
Plasminogen activator (TPA), 1333, 1376, 1380 
combined with heparin, 1376 
comparison with other thrombolytic agents, 
1375, 1375t, 1376 
Plasminogen molecule, single-chain, 1375 
Platelet(s), 1373. See also Antiplatelet agents 
activation and aggregation, 1377, 1393 
aspirin effects on, 1373 
Platelet-active drugs, 1373-1374. See also 
Antiplatelet agents 
Positron emission tomography (PET), 1389 
Potassium, repletion of. 1365 
PR segment 
depression, 1358 
displacement, 1363 
Practice guidelines, 1332-1333 
executive summary of, 1333-1335 
function of, 1333 
Practice patterns, variation in, 1357 
Prehospital issues related to acute myocardial 
infarction, 1333 
emergency medical services ystems, 1338 1339 
intervention strategies, 1338 
recognition and management, 1338 
recommendations, 1337 
thrombolysis, 1339-1340 
Preload, 1354, 1372 
reduction of, 1372 
in left vcntricular dysfunction, 1359 
in right ventricular infarction and dysfunction. 
1360, 1361 
Premature ventricular complexes, 1381 
Pressure gradient, in right ventricular dysfunction, 
1360 
Primary Angioplasty in Myocardial Infarction 
investigators. See PAMI 
Proarrhythmia, procainamide-related, 1381 
Procainamide, 1335, 1356, 1364 
adverse ffects, 1381 
pharmacology, 1381 
for ventricular tachycardia, 1364, 1365 
Procedures, changes in. 1337 
"Process of carc." 1336 
Progestins, 1399 
Propranolol, 1381 
for secondary prevention, 1397 
Prourokinase, 1376 
Pseudoaneurysm, 1359 
cardiac rupture and. 1359 
Psychological support, during hospitalization, 1356 
Public service personnel, training of, 1338-1339 
Pulmonary artery, oxygen saturation in, 1370 
Pulmonary artery wedge pressure, 1370 
in right vcntricular ischemia, 1360 
Pyrophosphate. See Yechnetium-99m 
pyrophosphatc 
Q 
Q wave, 1359, 1395 
Q wave myocardial infarction, 1345 
QRS complex, 1391 
narrow, atropine for, 1344 
QT interval, prolonged, 1384 
Quinapril, 1383 
Quinidine, 1364 
R 
Radinuclide studies. See also Scintigraphy 
Radionuclide studies 
in diagnosis of acute myocardial infarction, 1389 
for discharge, I335 
Rales, 1348 
Ramipril, 1383, 1397 
"Rebound effect," 1379 
Recurrent myocardial infarction, nondiagnostic 
ECG changes, 1353 
Refractory, period, lengthening of, 13811 
Rehabilitation. See Cardiac rehabilitation 
Rehospitalization, 1353 
Reinfarction, 1358-1360, 1384 
nifedipine effects on, 1383 
PTCA and, compared with thrombolytic therapy, 
1351 
time factor in, 1334 
verapamil effects on, 1384 
Reperfusion era, 1337 
Reperfusion therapy. See also Thrombolytic therapy 
clinical markers of, 1393 
early, 1333 
indications for, 1337 
prehospital, 1338 
to reduce hospital stay, 1356 
time delay in achieving, 1351 
timing for, 1338 
Repo[arization, 1354 
Respiratory depression, morphine-induced. 1355 
Restenosis, 1398 
Reteplase, 1376 
Revascularizatiou, 1337 
delays in, 1350 
effect on clinical outcome, 1353 
myocardial infarction during, 1395 
patient selection for, 1335 
in suspected myocardial infarction, 1353 
use of heparin in, 1378 
Rhythm disturbances. See also Arrhythmias 
atrial fibrillation, 1363-1364. See also Atrial 
fibrillation 
bradyarrhythmias nd heart block, 1366-1368. 
See also Bradyarrhythmias; Heart block 
ventricular tachycardia/ventricular fibrillation, 
1364-1365. See also Ventricular fibrillation; 
Ventricular tachycardia 
Right ventricular infarction and dysfunction, 1343, 
1360, 1368 
anatomic and physiologic onsiderations in, 1360 
clinical diagnosis of, 1360, 1361 
clinical presentation for, 1361 
management of, 1361, 1361t 
prognosis, 1361 
Risk factors, modification of, 1399 
Risk stratification, 1345, 1345f, 1346 
for discharge from hospital, 1386, 1387. 1388- 
1389 
in non-ST-segment elevation, 1352-1354 
"Rule out" MI, 1345 
Rupture. See also under Plaque 
intraventricular septum, 1371 
left ventricular free wall, 1371 
ventricular, 1370 
S 
Saline, normal, 1361 
Salvage procedures, PTCA for, compared with 
thrombolytic therapy. 13511 
Salvage procedures, thrombolytic therapy and, 1347 
Saphenous vein bypass graft, atherosclerosis in, 
1395 
SAVE (Survival and Ventricular Enlargement) 
trial, 1397 
Scandinavian Simvastin Survival Study, 1395 
SCATI study, 1378 
Scintigraphy. See also Radionuclide studies 
pyrophosphate. See Technetium-99m 
pyrophosphate 
stress, 1386, 1388 
Second International Study of Infarct Survival. See 
ISIS-2 
Second Leicester Intravenous Magnesium 
Intervention Trial trial. See LIMIT-2 trial 
Secondary prevention 
angiotensin-converting e ~'me inhibitors and, 
1397 
antiarrhythmic agents, 1399 
anticoagulants, 1398 
antioxidants, 1398 
/3-adrenoceptor blockade, 1397-1398 
calcium channel blockers, 1398 
estrogen replacement therapy, 1399 
long-term use of aspirin, 1397 
management of lipids, 1395-1396 
smoking cessation, 1395-1396 
Secondary Prevention Reinfarction Israeli 
Nifedipine Trial. See SPRINT 
Serum cardiac markers, 1334, 1340, 1346 
measurement of, 1356 
Sestamibi. See Technetium-99m sestamibi 
Sexual activity,, 140I 
Shock, cardiogenic, 1369 
absence of, 1356 
emergency or urgent coronary artery bypass graft 
surgery for, 1351 
intra-aortic balloon counterpulsation i , 1362 
intra-arterial pressure monitoring in, 1362 
in left ventricular dysfunction, 1359-1360 
in right ventricular infarction and dysfunction, 
1360 
treatment of, 1335 
in ventricular septal defect, 1371 
SHOCK (Should We Emergently Revascularize 
Occluded Coronaries for Cardiogenic 
Shock?) Registry, 1359-1360 
Should We Emergently Revascularize Occluded 
Coronaries for Cardiogenic Shock? 
Registry. See SHOCK Registry 
Should We Intervene Following Thrombolysis? 
study. See SWIFT study 
Shunting, left-to-right, 1370 
Simvastatin, for secondary prevention, 1395 
Sinus bradycardia 
atropine for, 1344 
background, epidemiulogy and importance of, 
1366 
pacing for, 1367 
treatment of, 1335, 1366 
Sinus tachycardia, 1348 
SMILE (Survival of Myocardial Infarction: Long 
Term Evaluation) study, 1382 
Smoking cessation, 1335, 1396 
effects of, 1356 
Social integration, 1400 
Social support, 1400 
Sodium nitroprusside, 1362 
for left ventricular dysfunction, 1359 
SOLVD (Studies of Left Ventricular Dysfunction) 
trial, 1397 
Sotalol, 1364 
SPRINT (Secondary Prevention Reinfarction 
Israeli Nifedipine Trial), 1383 
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ST-segment 
depression, 1352 
exercise-induced, mortality rates related to, 
1387 
mortality rates associated with, effect of 
thrombolytic therapy on, 1353 
elevation, 1333, 1334, 1337, 1340, 1377, 1378, 
1387 
angiotensin-converting e ~me inbibitors for, 
1382 
diagnostic and treatment measures for, 1350t 
early angiography in, 1351 
management of, 1345f, 1346 
mortality risk and, 1340, 1356, 1357f 
o~gen administration i , 1343 
in pericarditis, 1358 
in reinfarction, 1358 
in right ventricular ischemia, 1360 
thrombolytic therapy for, 1346, 1347, 1347f 
ST-T wave, in cardiac rupture, 1359 
Staff-patient ratios, 1357 
Staphylokinase, 1376 
Stenosis, 1356. See also Restenosis 
PTCA effects on, 1350 
PTCA in, 1393, 1394 
remodeling of, 1394 
Stool softeners, 1355 
Streptokinase (SK), 1350, 1375, 1376, 1380 
combined with 
alteplase, 1376 
aspirin, 1344, 1375 
heparin, 1376, 1377, 1378 
comparison with other thrombolytic agents, 
1375, 1375t, 1376 
efficacy ira acute myocardial infarction, 1375 
reuse of, 1376 
in ST-segment depression, 1352 
Stroke, 1334 
hemorrhagic, risk for, aspirin and, 1374 
PTGA and, compared with thrombolytic therapy, 
1351 
rate of, effect of heparin on, 1378, 1379 
thrombolytic therapy-related, risk for, 1349, 
1349f 
Studies of Left Ventricular Dysfunction trial. See 
SOLVD trial 
Stunning, 1388-1389 
right ventricular, 1360 
Sudden cardiac death 
aspirin effects on, 1396 
causes of, 1337 
occurrence of, 1355-1356 
risk for, 1338-i339, 1391 
Sulfinpyrazone, 1344, 1396 
Superoxide, production of, 1372 
Superoxide dismutase, 1398 
Surgery. See also specific procedure 
coronary artery graft. See Coronary artery artery 
graft surgery. 
indications for, 1335 
for mechanical defects repair, 1368 
minimum operative caseload, 1371 
volume of, relation to outcome, 1371 
Survival and Ventricular Enlargement trial. See 
SAVE trial 
Survival of Myocardial Infarction: Long Term 
Evaluation study. See SMILE study 
SWIFT (Should We Intervene Following 
Thrombolysis?) stud,,,, 1394 
Sympathetic nervous ystem 
overactivity of, 1355 
stimulation, minimizing of, 1354 
Systolic dysfunction, 1335, 1392 
ACE inhibitors for, 1334 
right ventricular, 1360 
Systolic function, 1333 
digitalis effects on, 1386 
nitrate effects on, 1372 
T 
T wave, in pericarditis, 1358 
Tachyarrhythmias, ventricular. 1368 
coronary artery bypass graft surgery for, 1369 
Tachycardia, 1339, 1343. See also Sinus tachycardia; 
Ventricular tachycardia 
TAMI (Thrombolysis and Angioplasty in 
Myocardial Infarction) trials, 1363, 1393, 
1394 
Tamponade. See also Cardiac tamponade 
pericardial, 1370 
T-wave abnormalities, 1352 
Technetium-99m pyrophosphate, 1389 
Technetium-99m sestamibi. 1387, 1388, 1389 
in emergency department, 1346 
for infarct size measurement, 1389 
Tertiary centers, triage to, 1338 
Thallium-201 imaging, 1387, 1389 
in emergency department, 1346 
Thrombin, 1378 
clot-bound, 1377 
inhibition of, 1377 
by heparin, 1379 
Thrombolysis n Myocardial Infarction. See TIMI 
Thrombolytic therapy, 1333, 1336. 1337, 1340, 1352, 
1359, 1383. See also Reperfusion therapy; 
specific agent 
for accelerated i ioventricular rhythm, 1365 
ACE inhibitor use after, 1383 
adverse ffects, 1333 
in atrial fibrillation, 1363 
background, 1374, 1375 
benefits in specific patient subgroups, 1376 
cardiac rupture from, 1359 
comparative efficacy, 1376 
compared with PTCA, 1350-1351 
comparison of agents, 1375, 1375t 
contraindications/cautions related to, 1345, 1348, 
1349t 
coronary angiography and possible percutaneous 
transluminal coronary angioplasty after. 
1392 
coronary artery bypass graft surgeu after, 1369 
current use rates for, 1377 
decision for, influences on, 1347. 1347f, 1348 
early, 1350 
effect on mortality, rate, 1333 
effect on outcome in nondiagnostic 
electrocardiographic changes, 1352 
exercise testing and, 1387 
failed, coronary angiography and percutaneous 
transluminal coronary angioplasty after, 
1392-1393 
general mechanism of action and 
pharmacological properties, 1375 
heparin administration after, 1334 
indications for, 1345 
with intra-aortic balloon pump, 1363 
intravenous, efficacy in acute myocardial 
infarction, 1375 
in ischemic-type chest discomfort, 1353 
mortality rates and, 1387 
ST-segment depression and, 1352 
ST-segment elevation and, 1352 
net clinical benefit of, 1348 
in nondiagnostic ECG changes, 1353 
prehospital-initiated, 1339-i340 
"door-to-door" needle time. 1339 
outcome associated with, 1339 
primary PTCA as alternative to, 1350 
recommendations, 1346-1349 
regimens, recommendations for selecting, 1376 
in right ventricular ischemia/infarction, 1361 
risk of stroke and, 1348, 1349f 
successful, routine coronary angiography and 
percutaneous transluminal coronary 
angioplasty after, 1394 
time-dependent benefits of, 1337 
timing of, 1333 
use of heparin in, 1379 
Thrombosis, thrombus, 1373, 1376 
arterial, 1362 
formation of, 1377 
mural, 1334 
occlusive. 1393 
prevention of, role of aspirin in, 1373-1374 
rccurrrent, discontinuation of heparin and, 1379 
Thromboxane Ae. production of, aspirin effects on, 
1344 
Ticlodipine, 1344, 1396 
action of, 1374 
Time factors, related to recogmtlon and 
management of myocardial infarction, 1338, 
1339 
"'door-to-door" needle time, 1339 
TIMI (Thrombolysis n Myocardial Infarction) flow 
rates, 1350 
TIMI-II trial, 1369, 1382 
TIMI-IIB trial, 1394 
TIMI-IIIb trial, 1353, 1354 
TIMI-9B trial, 1380 
Yimolol, for secondary prevention, 1397 
Tissue plasminogen activator. See Plasminogen 
activator 
TNK-plasminogen activator, I376 
Tomography. See also Computed tomography 
positron emission, 1389 
Yorsade de pointes, 1381, 1384 
TRACE (Trandolapril Cardiac Evaluation) trial, 
1397 
Trandolapril, 1397 
Trandolapril Cardiac Evaluation trial. See TRACE 
trial 
Transmural myocardial infarction, pericarditis in, 
1358 
Transmural necrosis, 1374 
Transplantation. See Cardiac transplantation 
Transport imes, 1338, I339 
Transportation, emergency, i338 
Treadmill testing, prediction of mortality, and, 1391 
Treatment of myocardial infarction 
changes in, 1337 
prehospital. 1333 
seeking of. patient delay in, 1338 
timing of, 1338, 1339 
TRENT (Trial of Early Nifedipine Treatment in 
Acute Myocardial Infarction), 1383 
Triage, 1338, 1339, 1340, 1357 
Trial of Early Nifedipine Treatment in Acute 
Myocardial Infarction. See TRENT 
Troponin I (cTnI), 1334, 1341, 1354, 1356 
Troponin T (cTnT), 1334. 1341, 1356 
U 
Unstable ischemic syndromes, 1362 
Urokinase, use of heparin with, 1377, 1378 
V 
V wave, 1370 
Vagal tone, decreased, 1391 
Valsalva maneuver, avoidance of, 1354 
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Vascular endothelium, ACE inhibitors arising from. 
1397 
Vasoconstriction, 1343, 1372 
peripheral, 1354 
Vasoconstrictors. inotropic agents, 1385 
Vasndilation, vasodilators, 1362 
nitrates, 1371-1372 
with nitroglycerin. 1343 
Vaughan-Williams classes, 13811, 1381 
Venous access, peripheral, 1342 
Ventilation 
mechanical, 1343 
morphine ffects on, 1355 
Vcntilation-perfusion mismatch, 1343 
Vcntricular arrhythmias. See Arrhythmias, 
ventricular 
Ventricular asystole, 1366 
atropine for, 1344 
Ventrieular capture, loss of. 1368 
Ventricular ectopy, 1391 
lidocaine for, 1381 
Ventricular fibrillation (VF), 1364, 1381 
amiodarone for, 1381 
background, 1364-1365 
bretylium for, 1380 
defibrillation shocks for. 1339 
early sustained, absence of. 1356 
ischemia-induced, 1338-1339 
lidocaine for, 1381 
management strategies for, 1365 
primary, 1364-1366 
procainamide for, 1381 
secondary, 1364 
sustained, 1365 
treatment of, 1335 
Ventricular filling, shifts in, 1354 
Ventricular function. ,gee also Left ventricular 
function: Right ventricular infarction and 
dysfunction 
impairment of, ACE inhibitors for, 1334 
Ventricular premature beats, 1364, 1391 
Ventricular rate, in atrial fibrillation, 1363 
Ventricular response, rapid, 1383 
Ventricular rupture, 1370 
Ventricular septal defect (VSD), postinfarction, 1370 
management of, 1371 
emergency or urgent coronary arter~ bypass 
graft surgery, for, 1351 
Ventricular tachycardia (VT), 1356. 1364, 1381 
amiodarone for, 1381 
background, 1365 
bretylium for, 1380 1381 
early sustained, absence of, 1356 
lidocaine for, 1381 
management strategies fi}r, 1365 
monomorphic, 1335, 1364, 1365, 1366 
sustained, 1391 
nonsustained, 1365. 1391 
polymorphic, 1364, 1365, 1366 
procainamide for, 1381 
Verapamil, 1384 
for atrial fibrillation, 1363 
contraindications to, 1383 
pharmacology, 1383-1384 
Veterans Administration Cooperative Study, 1374 
Viability. See Myocardial viability 
Vitamin E, 1398 
Volume 
depletion, 1385 
expansion, 1335 
loading, in right ventricular ischemia/infarction, 
1361 
W 
Walking, 141)1 
Warfarin, lk)r secondary prevention, 1398 
Water. See also Fluid 
lung, excessive, 1343 
Weight, 1335, 1349 
Women 
estrogen replacement therapy for, 1399 
symptoms of acute myocardial infarction in, 1340 
Work, return to, 1401 
World Health Organization (WHO), 1340, 1341 
Writing groups, 1332-1333 
Z 
Zofcnopril. 1383 
